Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 8

Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study

Authors Mehta R, Kelleher D, Preece A, Hughes S, Crater G

Published Date March 2013 Volume 2013:8 Pages 159—167


Received 29 November 2012, Accepted 29 January 2013, Published 27 March 2013

Rashmi Mehta,1 Dennis Kelleher,1 Andrew Preece,2 Stephen Hughes,3 Glenn Crater4

1Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, NC, USA; 2Respiratory Medicines Development Center, GlaxoSmithKline, Stockley Park West, UK; 3GlaxoSmithKline R&D, Bioanalytical Sciences and Toxicokinetics, Drug Metabolism and Pharmacokinetics, Ware, UK; 4Respiratory Medicine Development Center, GlaxoSmithKline, Mississauga, ON, Canada

Background: The combination of umeclidinium (UMEC), a long-acting muscarinic receptor antagonist, and vilanterol (VI), a selective long-acting ß2 agonist, is in development for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the pharmacokinetics, safety and tolerability, and pharmacodynamics of once-daily, inhaled UMEC and UMEC/VI when co-administered with oral verapamil, a moderate P-glycoprotein transporter and moderate cytochrome P450 3A4 (CYP3A4) inhibitor frequently used by patients with COPD and cardiovascular comorbidities.
Methods: Subjects were randomized to one of two 13-day treatment regimens: UMEC 500 µg or UMEC 500 µg/VI 25 µg. All subjects received a single tablet containing 240 mg verapamil on each of days 9–13.
Results: Repeat doses of UMEC and UMEC/VI in combination with and without verapamil were safe and well tolerated. There was no increase in systemic exposure of UMEC when administered in combination with VI compared to UMEC alone. UMEC maximum concentration was similar with or without verapamil; a moderate increase in UMEC area under the curve (approximately 1.4-fold) was observed with verapamil. Verapamil did not increase systemic exposure to VI following administration of the UMEC/VI combination.
Conclusion: Administration of UMEC and UMEC/VI combination was well tolerated and did not show clinically relevant increases in systemic exposure for either drug. The UMEC/VI combination is unlikely to have a clinically meaningful drug–drug interaction with moderate P-glycoprotein transporter and CYP3A4 inhibitor drugs.

Keywords: umeclidinium, vilanterol, verapamil, long-acting muscarinic antagonist, long-acting ß2 agonist

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Readers of this article also read:

A study on the hemocompatibility of dendronized chitosan derivatives in red blood cells

Zhou YF, Li JM, Lu F, Deng JJ, Zhang JH, Fang PJ, Peng XS, Zhou SF

Drug Design, Development and Therapy 2015, 9:2635-2645

Published Date: 14 May 2015

Functionalized magnetic iron oxide/alginate core-shell nanoparticles for targeting hyperthermia

Liao SH, Liu CH, Bastakoti BP, Suzuki N, Chang Y, Yamauchi Y, Lin FH, Wu KCW

International Journal of Nanomedicine 2015, 10:3315-3328

Published Date: 4 May 2015

Efficacy and feasibility of the immunomagnetic separation based diagnosis for detecting sentinel lymph node metastasis from breast cancer

Zhi XC, Zhang M, Meng TT, Zhang XB, Shi ZD, Liu Y, Liu JJ, Zhang S, Zhang J

International Journal of Nanomedicine 2015, 10:2775-2784

Published Date: 7 April 2015

Dynamic hyperinflation and dyspnea during the 6-minute walk test in stable chronic obstructive pulmonary disease patients

Satake M, Shioya T, Uemura S, Takahashi H, Sugawara K, Kasai C, Kiyokawa N, Watanabe T, Sato S, Kawagoshi A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:153-158

Published Date: 17 January 2015

Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity

Ross KA, Loyd H, Wu W, Huntimer L, Ahmed S, Sambol A, Broderick S, Flickinger Z, Rajan K, Bronich T, Mallapragada S, Wannemuehler MJ, Carpenter S, Narasimhan B

International Journal of Nanomedicine 2015, 10:229-243

Published Date: 30 December 2014